Silexion Therapeutics Corp (SLXN) Q1 2026 Earnings Call Transcript

Why It Matters

The strong commercial traction and robust cash position position Syndax to scale its first‑in‑class therapies without additional financing, accelerating market share in high‑unmet‑need AML and GVHD segments.

Key Takeaways

• RevuForge revenue $124.8M, 38% QoQ growth.
• Nictimvo net revenue $151.6M, 22% sequential increase.
• Formulary coverage 97% for NPM1 label within four months.
• Cash runway $394M, no new funding needed.
• Combination use with Ven/Aza up to 40% of prescriptions.

Pulse Analysis

Menin inhibition has emerged as a transformative approach for acute myeloid leukemia, targeting the KMT2A and NPM1 mutations that drive aggressive disease. Syndax’s RevuForge, the first FDA‑approved menin inhibitor, capitalizes on this biology, offering a differentiated efficacy profile that has quickly translated into strong market uptake. By securing near‑universal formulary placement for the expanded NPM1 indication within months, the company has set a new benchmark for launch speed in the oncology space, expanding its addressable patient pool to over 6,500 individuals in the United States.

The commercial data underscore a virtuous cycle of adoption and combination therapy. RevuForge’s quarter‑over‑quarter revenue jump of 38% and a 35% rise in prescriptions reflect genuine physician demand, further amplified by a 40% combination rate with Venetoclax/Azacitidine—regimens that enhance depth of response. Real‑world evidence from Moffitt Cancer Center, showing a 77% overall response and 75% MRD‑negative rate, reinforces confidence among oncologists and supports broader payer acceptance. Meanwhile, Nictimvo’s rapid penetration of 90% of U.S. bone marrow transplant centers and high ten‑month persistency signal durable revenue streams in the chronic GVHD market.

Looking ahead, Syndax’s pipeline adds strategic depth. The phase 2 MaxSpire trial of axatilamab in idiopathic pulmonary fibrosis targets a $2‑billion unmet‑need market, with top‑line data expected in 2026. Pivotal phase 3 studies for Nictimvo in GVHD and frontline menin inhibitor trials in newly diagnosed AML position the company to capture additional market share and extend its product lifecycle. Coupled with a $394 million cash reserve and disciplined expense guidance, Syndax is well‑placed to fund these initiatives and drive sustained growth without dilutive financing.